What causes hlh in babies

Overview

Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening condition that affects infants and young children. It is characterized by an overactive immune system that damages the body's own tissues and organs. Instead of fighting off infections or abnormal cells, the immune system becomes dysregulated, leading to a widespread inflammatory response. This uncontrolled immune activation can cause severe damage to vital organs like the liver, spleen, brain, and bone marrow.

Causes of HLH in Babies

Primary (Familial) HLH

The most common cause of HLH in babies is genetic. Primary HLH, also known as Familial HLH (FHL), is an inherited disorder. In these cases, specific gene mutations are passed down from parents to their child, often through an autosomal recessive pattern. These genetic defects impair the function of certain immune cells, particularly cytotoxic T lymphocytes and Natural Killer (NK) cells. These cells are crucial for clearing infected cells and abnormal cells. When they don't function correctly, the immune system cannot properly 'turn off' itself after an infection or other trigger, leading to a persistent and damaging inflammatory state. Around 50-60% of all HLH cases are believed to be genetic in origin, with several different genes identified as potential culprits, including PRF1, UNC13D, STX11, and STXBP2.

Secondary HLH

In the remaining cases, HLH can be acquired, meaning it is not directly inherited but develops due to other underlying conditions or triggers. This is known as secondary HLH. In infants, common triggers for secondary HLH include:

• Infections: Viral infections are the most frequent culprits, with the Epstein-Barr virus (EBV) being a well-known trigger. Other viruses, bacteria, fungi, and parasitic infections can also precipitate HLH. The immune system's response to the infection is so robust that it becomes overactive and starts attacking the body's own cells.
• Malignancies: While less common in very young infants compared to older children, certain types of cancers, particularly leukemias and lymphomas, can sometimes trigger HLH.
• Immunodeficiency Syndromes: Babies with underlying primary immunodeficiency disorders may be more susceptible to developing HLH.
• Other Conditions: Less commonly, conditions like autoimmune diseases or severe organ transplant rejection can also lead to secondary HLH.

Mechanism of HLH

Regardless of the cause, the underlying mechanism of HLH involves a breakdown in immune regulation. Normally, immune cells like cytotoxic T cells and NK cells are responsible for identifying and destroying foreign invaders (like viruses) or abnormal cells (like cancer cells). They also play a role in 'cleaning up' after an immune response. In HLH, these cells either don't function correctly or their activation is not properly controlled. This leads to:

• Excessive Cytokine Production: Immune cells release a flood of inflammatory signaling molecules called cytokines (a 'cytokine storm'). These cytokines recruit more immune cells and amplify the inflammatory response.
• Hemophagocytosis: Activated macrophages, another type of immune cell, begin to engulf (phagocytose) blood cells (red blood cells, white blood cells, platelets) and other cellular debris. This process, known as hemophagocytosis, is a hallmark of HLH and contributes to the cytopenias (low blood counts) seen in affected infants.
• Organ Damage: The relentless inflammation and the accumulation of immune cells and debris in various organs lead to organomegaly (enlarged liver and spleen), jaundice, neurological symptoms, and bone marrow dysfunction.

Symptoms and Diagnosis

Symptoms of HLH in babies often appear within the first few months of life, typically by 3 months of age. They can be non-specific and mimic other serious illnesses, making diagnosis challenging. Common signs include fever that doesn't respond to antibiotics, extreme irritability or lethargy, poor feeding, vomiting, diarrhea, enlarged liver and spleen (hepatosplenomegaly), jaundice, and bleeding tendencies. Neurological symptoms like seizures or developmental delay can also occur. Diagnosis requires a combination of clinical suspicion and specific laboratory tests that reveal characteristic findings such as low blood counts, elevated liver enzymes, low ferritin levels, high triglycerides, low fibrinogen, and evidence of hemophagocytosis in bone marrow or other tissues. Genetic testing is often performed to identify underlying mutations in familial HLH.

Prognosis and Treatment

HLH is a medical emergency. Without prompt and aggressive treatment, the mortality rate is very high. Treatment aims to suppress the overactive immune system and address any underlying triggers. This typically involves chemotherapy to reduce immune cell proliferation and corticosteroids to control inflammation. Immunosuppressive therapies, such as cyclosporine, may also be used. For primary HLH, a bone marrow or stem cell transplant is often the definitive cure, as it replaces the defective immune system with a healthy one. Early recognition and access to specialized care are crucial for improving outcomes in infants with HLH.